Femasys Inc. (NASDAQ:FEMY) Short Interest Down 47.8% in December

Femasys Inc. (NASDAQ:FEMY) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 225,800 shares, a decrease of 47.8% from the December 15th total of 432,800 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily volume of 183,100 shares, the short-interest ratio is currently 1.2 days.

Institutional Investors Weigh In On Femasys

Several institutional investors and hedge funds have recently added to or reduced their stakes in FEMY. Aljian Capital Management LLC acquired a new position in Femasys during the third quarter valued at approximately $27,000. XTX Topco Ltd grew its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after acquiring an additional 17,473 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Stock Performance

Shares of Femasys stock remained flat at $1.05 during midday trading on Tuesday. 59,187 shares of the stock were exchanged, compared to its average volume of 73,861. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40. The firm has a 50 day moving average of $1.09 and a 200 day moving average of $1.12. The stock has a market capitalization of $24.04 million, a P/E ratio of -1.30 and a beta of -2.82.

Femasys (NASDAQ:FEMY) last posted its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, equities research analysts predict that Femasys will post -0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on FEMY shares. Chardan Capital dropped their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Femasys in a research report on Tuesday, December 3rd.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.